Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Exclusion Criteria

• •Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial; CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms
• •Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month
• •Patients may not have had prior bevacizumab, based on case reports of tracheoesophageal fistula in patients treated with bevacizumab and radiotherapy
• •Eastern Cooperative Oncology Group (ECOG) performance status =\<2
• •Age 18 years or older
• •Life expectancy of \>= 3 months
• •Patients must have normal organ and marrow function within 30 days of registration, as defined below:
• •* Absolute neutrophil count \>= 500/mcL
• •* Hemoglobin \>= 8.0 g/dL
• •* Platelets \>= 50,000/mcL
• •* Total bilirubin within normal institutional limits
• •* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 X institutional upper limit of normal if liver metastases are present
• •Women of childbearing potential must have a negative pregnancy test within 14 days of registration
• •Patients must have the ability to understand and the willingness to sign a written informed consent document
• •Patients who have had prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy within 1 month of enrollment
• •Patients who have had any prior bevacizumab, due to case reports suggesting a possible risk of severe toxicity in combination with radiotherapy
• •Patients with radiographic or clinical findings of spinal cord compression or cauda equina syndrome with neurologic deficit thought to be due to malignancy
• •Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy
• •Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose
• •Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer
• •Severe, active co-morbidity, defined as follows:
• •* Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration;
• •* Transmural myocardial infarction within the last 6 months prior to registration;
• •* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
• •* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration;
• •* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease if the liver is involved with metastatic disease;
• •* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count \< 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count \>= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
• •Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatment